Table 3.

Relationship between baseline BMI and incidence of any breast cancer according to treatment received and trial

	IBIS-I	IBIS-II
	HR (95% CI)	HR (95% CI)
Placebo	1.01 (0.99–1.03)	1.23 (1.09–1.38)
Tamoxifen	1.02 (0. 99–1.04)
Anastrozole		1.14 (0.93–1.39)
P-interaction	0.62	0.55

Analyses adjusted for age, HRT, current or previous history of smoking, IBIS-I participation (IBIS-II analyses only) and menopausal status (IBIS-I analyses only)

Hazard ratios for continuous estimates are per 5 unit increase in baseline BMI